Histopathologic Features and Clinical Outcome of Anaplastic Thyroid Carcinoma with a Minor Anaplastic Component.


Journal

Endocrine pathology
ISSN: 1559-0097
Titre abrégé: Endocr Pathol
Pays: United States
ID NLM: 9009288

Informations de publication

Date de publication:
Sep 2020
Historique:
pubmed: 24 5 2020
medline: 2 6 2021
entrez: 24 5 2020
Statut: ppublish

Résumé

Although prior studies have reported that patients with anaplastic thyroid carcinoma (ATC) with a focal anaplastic component may have a prolonged survival compared to other ATC patients, the outcome data are limited. We evaluated a cohort of ATC resected between 2003 and 2018. Tumor slides were reviewed to confirm the diagnosis and to identify cases with a minor ATC component (defined as comprising < 10% of the tumor). We evaluated the clinical outcome of these patients compared to that of all other cohort patients (characterized as having conventional ATC). Our cohort was composed of 24 cases of ATC that underwent resection, including 8 (33%) with a minor ATC component. Tumors with a minor ATC component were predominantly associated with papillary thyroid carcinoma. For patients with tumors with a minor ATC component, the 1-year and 2-year survival rates and median survival for patients who died of disease were 88%, 43%, and 17 months (range 6-73 months), respectively. In comparison, for patients with conventional ATC, the 1-year and 2-year survival rates and median survival for patients who died of disease were 56%, 44%, and 7 months (range 2-26 months), respectively. There was no difference in 1- and 2-year survival or overall survival by Kaplan-Meier analysis for patients with tumors with a minor ATC component and those with conventional ATC. In conclusion, the difference in overall survival between ATC groups in our cohort was not significant; however, this could be due to the small cohort size or due to characteristics of our group with a minor ATC component; that is, no tumors in this group were limited to the thyroid (stage IVA), resectability with negative margins was infrequent, and 38% of this group had distant metastases at diagnosis (stage IVC).

Identifiants

pubmed: 32445173
doi: 10.1007/s12022-020-09627-0
pii: 10.1007/s12022-020-09627-0
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

283-290

Auteurs

Kristine S Wong (KS)

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Jochen H Lorch (JH)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Erik K Alexander (EK)

Division of Endocrinology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Ellen Marqusee (E)

Division of Endocrinology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Nancy L Cho (NL)

Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Matthew A Nehs (MA)

Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Gerard M Doherty (GM)

Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Justine A Barletta (JA)

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. jbarletta@bwh.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH